Represented Brightline Ventures in connection with its venture capital investment in Heat Biologics, Inc.

Heat Biologics is a clinical-stage immunotherapy company focused on developing novel, off-the-shelf drugs that modulate the immune system to combat a wide range of cancers and viral infections, including HIV, Hepatitis C and influenza. The funds raised by Heat will primarily be utilized to expedite ongoing clinical trials of Heat’s therapeutic vaccines to treat Non Small Cell Lung Cancer. A Seward & Kissel team led by partner Craig Sklar and associates Meir Grossman and Gary Anderson represented Brightline Ventures in connection with its investment in Heat Biologics.